TRDX Trend Exploration Inc (PK)

SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) today announces it has recently executed a Definitive Sublicense Agreement with Montreal-based Genesis Bio Pharma, Inc. to acquire the exclusive worldwide sublicense for a new compound in development for the treatment of Painful Diabetic Neuropathy (PDN).

ABOUT PDN:

PDN is one of many complications of diabetes. Forty to fifty percent of diabetic patients may develop PDN over 15 to 20 years. PDN is present in 11.6% of patients with Type I diabetes and 32.1% of patients with Type II diabetes. PDN may present itself as a progressive build-up of unpleasant sensory symptoms including tingling (paraesthesia), burning pain, radiating pain down the legs and toes and lancinating or contact pain. The pain is more severe during the night and often prevents sleep. Some patients may be in a constant state of tiredness because of sleep deprivation while others are unable to maintain employment.

Dr. Jan Stahl, CEO of TRDX, commented: "The signing of this Definitive Agreement is a major achievement for the development of our partnership with Genesis. We look forward to the closing and working with Genesis to continue the groundbreaking development to treat diabetic neuropathy."

Mr. Leo Stella, CEO of GENESIS Bio Pharma Inc., commented: "We are pleased with the signing of this Agreement and now look forward to the closing so we can move quickly to reach our goals by commencing the clinical trials as soon as possible."

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called "amide bonds").

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company's business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

Contact: SciMeDent Health Corp. f/k/a Trend Exploration, Inc. dmyers@cadenceconsultingllc.com 1-866-383-1374